BioSpace News Archive

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Wednesday, August 5, 2020.

Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company’s financial results and business highlights for the second quarter ended June 30, 2020 .

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today annou

Researchers from NCCN Member Institutions will evaluate futibatinib in order to improve treatment for cancers with FGFR aberrations.

Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and vi

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announces the completion of a study highlighting the performance of NeuCovix™, AXIM’s rapid test to measure levels of neutralizing anti-COVID-19 antibodies. The NeuCovix™ test was compared to a gold standard pseudovirus-based test. NeuCovix™ accurately classified serum

Companies will collaborate to invest in development and acquisition of acute-care health facilities through its health systems, Altus Health and Legent Health

Publix Pharmacy recently received the Specialty Pharmacy Patient Choice Award, presented by Zitter Insights, a division of Managed Markets Insights & Technology, in the Retail Pharmacy category.

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the initiation of a Phase 1/2a trial of the company’s lead product candidate, PIPE-505, a small molecule gamma secretase inhibitor (GSI), in sensorineural hearing loss (SNHL) associated with hearing speech in noisy environments.

CAGE Bio Inc., today announced discovery of a novel hand sanitizer that offers long-lasting protection from coronavirus and other harmful viruses, bacteria, and fungi.